- The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats
-
Safhi MM, Anwer T, Khan G, Siddiqui R, Moni Sivakumar S, Alam MF
- KMID: 2418999
- Korean J Physiol Pharmacol.
- 2018 Sep;22(5):493-501.
- doi: 10.4196/kjpp.2018.22.5.493
The present study was carried out with the hypothesis that combination of canagliflozin and omega-3 fatty acid may have potential effect on insulin level, insulin resistance, cardiac biomarkers, inflammatory cytokines... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
-
Hong JH
- KMID: 2451837
- J Korean Diabetes.
- 2019 Jun;20(2):87-91.
- doi: 10.4093/jkd.2019.20.2.87
Management of hyperglycemia limits progression of microvascular complications in type 2 diabetes mellitus (T2DM). According to large-scale randomized control studies to demonstrate the cardiovascular safety of sodium-glucose cotransporter 2 (SGLT2)... -
- CITED
-
- Close
- SHARE
-
- Close
- A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
-
Jung CH, Jang JE, Park JY
- KMID: 2174102
- Diabetes Metab J.
- 2014 Aug;38(4):261-273.
- doi: 10.4093/dmj.2014.38.4.261
Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
-
Kim GS, Park JH, Won JC
- KMID: 2450509
- Endocrinol Metab.
- 2019 Jun;34(2):106-116.
- doi: 10.3803/EnM.2019.34.2.106
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations
-
Lim S
- KMID: 2458961
- J Korean Diabetes.
- 2019 Sep;20(3):127-135.
- doi: 10.4093/jkd.2019.20.3.127
Diabetes mellitus (DM) is linked to poor outcomes after cardiovascular events and renal complications. Recently, novel antidiabetic agents, such as dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like... -
- CITED
-
- Close
- SHARE
-
- Close
